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Abstract
Background: Almost one third of the patients with candidemia develop septic shock. The understanding why
some patients do and others do not develop septic shock is very limited. The objective of this study was to identify
variables associated with septic shock development in a large population of patients with candidemia.
Methods: A post hoc analysis was performed on two prospective, multicenter cohort of patients with candidemia
from 12 hospitals in Spain and Italy. All episodes occurring from September 2016 to February 2018 were analyzed
to assess variables associated with septic shock development defined according to The Third International
Consensus Definition for Sepsis and Septic Shock (Sepsis-3).
Results: Of 317 candidemic patients, 99 (31.2%) presented septic shock attributable to candidemia. Multivariate logistic
regression analysis identifies the following factors associated with septic shock development: age > 50 years (OR 2.57,
95% CI 1.03–6.41, p = 0.04), abdominal source of the infection (OR 2.18, 95% CI 1.04–4.55, p = 0.04), and admission to a
general ward at the time of candidemia onset (OR 0.21, 95% CI, 0.12–0.44, p = 0.001). Septic shock development was
independently associated with a greater risk of 30-day mortality (OR 2.14, 95% CI 1.08–4.24, p = 0.02).
Conclusions: Age and abdominal source of the infection are the most important factors significantly associated with
the development of septic shock in patients with candidemia. Our findings suggest that host factors and source of the
infection may be more important for development of septic shock than intrinsic virulence factors of organisms.
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Introduction
Candida species has been reported as the most common
cause of fungal disease in septic shock, affecting 8–10%
of these patients [1–3]. Moreover, among patients devel-
oping septic shock, candidemia is actually considered
the clinical condition with the highest attributable mor-
tality, ranging from 54 to 66% [4–6]. The survival of
these patients is strictly related to a timely control of the
source and appropriate antifungal treatment [4, 5].
While candidemia has long been recognized as a trig-
ger for septic shock development, our understanding of
why patients with candidemia develop or not septic
shock has not been well addressed [7]. Literature on the
topic is very limited and difficult to interpret due to the
low number of patients included and the inconclusive
results reported [7].
Therefore, the aim of our study was to assess factors
associated with the development of septic shock in the
context of two large multicenter studies of patients with
candidemia.
Materials and methods
Study design, setting, and population
In the present report, we included data coming from
two separate studies. First is a prospective cohort assem-
bled within a quasi-experimental study aimed at asses-
sing the impact of an evidence-based intervention
bundle to improve the clinical management of candide-
mia (the CANDI-Bundle Study) that was conducted
from September 2016 to February 2018 in 11 hospitals
from Spain. Second is a prospective observational study
on candidemia that was conducted during the same
period at the University Hospital Santa Maria della Mis-
ericordia in Udine, Italy. The full results from both co-
horts are currently undergoing detailed analysis.
In order to ensure comparability, the same inclusion
and exclusion criteria, study definitions, patient follow-
up, and data collection procedures were applied in both
studies. However, for this post hoc analysis, we excluded
patients aged < 18 years old and those who had mixed
infection (concomitant blood culture positive for a bac-
terial pathogen).
The study was approved by the local institutional re-
view boards, and written patient consent was not re-
quired because of observational nature of this study.
Clinical data and definitions
Data were collected from patients’ hospital charts and
the laboratory database, which contains complete pro-
files for all candidemic patients. The main outcome
measured was development of septic shock attributable
to candidemia. Septic shock patients and non-septic
shock subgroups were compared to identify variables as-
sociated with septic shock development.
The following variables were explored as possibly asso-
ciated with septic shock development:
i. For patient variables, we considered age, sex,
hospital ward stay at the time of infection, Charlson
comorbidity index [8]),underlying diseases,
immunosuppressive therapy, history of previous
abdominal surgery (30 days preceding candidemia
onset), presence of central venous catheter (CVC)
at the time of candidemia, total parenteral nutrition,
and prior exposure to antimicrobial or antifungal
therapy (within previous 30 days).
ii. For infection variables, we considered source of
infection, pathogen species, and antifungal
resistance.
All patients were followed until discharge or death and
were assessed for survival on day 30.
Definitions
An episode of candidemia was defined as at least one
peripheral blood culture positive for Candida spp. Can-
didemia onset was defined as the date of collection of
the first blood culture yielding the study isolate.
Septic shock was determined according to The Third
International Consensus Definition for Sepsis and Septic
Shock (Sepsis-3) [9]. All clinical and laboratory data de-
fining septic shock were assessed within 24 h of the first
positive blood culture yielding Candida spp. Patients
were classified as having septic shock attributable to
Candida infection if vasopressors were required to
maintain a mean arterial pressure of ≥ 65 mmHg and
serum lactate level greater than 2 mmol/L [9]. Patients
who required vasopressors ≥ 24 h prior to the collection
of a blood culture subsequently positive for Candida
species were included in the non-septic shock group.
As for the source of infection, CVC-related candide-
mia was defined according to current guidelines [10, 11].
The urinary tract was considered to be the portal of
entry in patients with urological predisposing conditions
(i.e., manipulation or obstruction of the urinary tract)
and evidence of urinary tract infection caused by the
same Candida spp. [12]. The abdomen was considered
to be the origin of the candidemia when a patient had
evidence of abdominal infection and (i) a positive culture
from the intra-abdominal space was obtained during
surgery or by needle aspiration or (ii) no other apparent
sources of candidemia were detected [13–15]. When a
source of candidemia could not be identified, candide-
mia was defined as “primary.”
Initial antifungal therapy was considered as adequate if
at least one active drug according to in vitro susceptibil-
ity results was initiated at an appropriate dosage [10]
within the first 24 h after blood culture was obtained.
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Source control included CVC withdrawal and invasive
procedures to resolve urinary tract obstruction and
intra-abdominal abscess drainage, depending on the
source of candidemia. Source control was considered ad-
equate when performed within 24 h from candidemia
onset.
Neutropenia was defined as an absolute neutrophil
count< 500 cells/mm3 at the onset of candidemia.
Microbiological studies
Candida specie identification and in vitro antifungal ac-
tivity were assessed at participating hospitals using local
routine methods. Currently, two sets of two blood sam-
ples were collected from patients with a suspected
bloodstream infection. The blood samples were proc-
essed using a BACTEC 9240 system (Becton– Dickinson
Microbiology Systems, Franklin Lakes, NJ, USA) or
BACTE 860 system or BacTAlert (BioMérieux SA,
Marcy L’Etoile, France) with an incubation period of 5
days. If yeast cells were observed after microscopic
examination of a Gram stain, blood bottles were subcul-
tured into Sabouraud agar plates (BD BBL StrackerTM
PlatesTM, Heidelberg, Germany) and chromogenic
media (ChromAgar BioMerieux SA, Paris, France). In
vitro antifungal activity was studied by a commercial
microdilution method (YeastOne®Sensitre®, TREK Diag-
nostic Systems Ltd., East Grinstead, UK) or E test (Bio-
Mérieux SA, Paris, France), in accordance with the
manufacturer’s instructions.
Statistical analysis
Categorical variables are expressed as absolute numbers
and relative frequencies. Quantitative variables are pre-
sented as means and standard deviation (SD) if normally
distributed or as median and interquartile range (IQR) if
non-normally distributed. We compared continuous var-
iables between patients with or without septic shock
using the Student t test for normally distributed vari-
ables and the Mann-Whitney U test for non-normally
distributed variables. Categorical variables were evalu-
ated by using the chi-square or the two-tailed Fisher
exact test.
Variables associated with septic shock due to candidemia
in univariate analysis (p ≤ 0.20) were included in a logistic
regression analysis, and a backward stepwise approach was
used to identify those independently associated with septic
shock development (p < 0.05). All statistical analyses were
performed by using SPSS Statistics for MAC, Version 22.0
(SPSS Inc., Chicago, IL, USA).
Results
A total of 317 episodes of candidemia were included in
the study. Overall, 99 of the 317 patients (31.2%) fulfilled
the criteria for septic shock within the first 24 h after
blood culture was drawn, and 34.3% of them died in 30
days.
Clinical characteristics of study population
Demographics and baseline clinical features of study
population are shown in Table 1. Mean age was 65.4
years, and 184 patients were men (58.0%). Overall, 63
out of 317 (19.9%) episodes of candidemia occurred in
intensive care unit (ICU), and 254 (80.1%) occurred in
patients hospitalized in general wards, including 150
(47.3%) in internal medicine and 104 (32.8%) in surgical
wards.
The most common underlying condition was solid
tumor (35.9%) followed by cardiovascular disease
(32.2%) and diabetes mellitus (28.4%). Almost all pa-
tients had recently received antibiotic therapy (within
the previous 1 month). A CVC was in place in 225 out
of 317 patients (71.0%), with 158 of them receiving total
parenteral nutrition at the time of candidemia onset.
The most prevalent source of infection was the CVC
(44.5%) followed by the abdomen that was detected in
39 patients (12.3%). Source of candidemia remained un-
known in 98 (30.9%) patients.
As for species, C. albicans was the most frequent one
(42.3%) followed by C. glabrata (18.3%), C. parapsilosis
(17.4%), and C. tropicalis (9.1%).
Variables associated with septic shock attributable to
candidemia
Patients with septic shock attributable to candidemia (99
patients) and without septic shock (218 patients) were
compared (Table 1). There were no significant differ-
ences regarding sex, Charlson comorbidity index, under-
lying disease, and risk factors for candidemia and
Candida species. However, at univariate analysis, factors
associated with development of septic shock were as fol-
lows: age older than 50 years (92.9% vs 83.9%; p = 0.03),
hospitalization in ICU at the time of candidemia (37.4%
vs 11.9%, p = 0.001), and an abdominal source of the in-
fection (20.2% vs 8.7%; p = 0.006). A multivariate analysis
(Table 2) showed that older age (OR 2.57, 95% CI 1.03–
6.41, p = 0.04) and an abdominal source of the infection
(OR 2.18, 95% CI 1.04–4.55, p = 0.04) were independ-
ently associated with the development of septic shock in
candidemic patients. By contrast, being admitted to a
general ward at the time of candidemia onset was con-
sidered as a protective factor (OR 0.21, 95% CI 0.12–
0.44, p = 0.001).
Comparison between patients with and without intra-
abdominal origin of the infection is reported in Supple-
mentary material 1. As for infection management, echi-
nocandin was the most frequent initial antifungal agent,
prescribed in 57.7% of cases, followed by azoles in 35.3%
of patients. Although rates of initial echinocandin
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Table 1 Comparison of the main demographic and clinical characteristics of study population
Variable All episodes, N = 317 (%) Non-septic shock, N = 218 (%) Septic shock, N = 99 (%) p value
Demographics
Sex, male 184 (58.0) 141 (64.7) 43 (43.4) 0.17
Mean age (± SD), years 65.4 ± 17.0 65.2 ± 18.6 66.9 ± 15.2 0.77
Age ≥ 50 years 275 (86.4) 183 (83.9) 92 (92.9) 0.03
Median hospital stay until Candida BSI (IQR), days 16 (7–31) 17 (6–32) 14 (8–28) 0.18
Hospital ward stay at the time of candidemia onset
General ward 254 (80.1) 192 (88.1) 62 (62.6) 0.001
Intensive care unit 63 (19.9) 26 (11.9) 37 (37.4)
Charlson comorbidity index 3.4 ± 2.7 3.4 ± 2.6 3.3 ± 2.8 0.71
Underlying condition
Solid tumor 114 (35.9) 77 (35.3) 37 (37.4) 0.80
Cardiovascular disease 102 (32.2) 69 (31.7) 33 (33.3) 0.79
Diabetes mellitus 90 (28.4) 57 (26.1) 33 (33.3) 0.22
Chronic Lung disease 51 (16.1) 35 (16.1) 16 (16.2) 1
Chronic kidney failure 50 (15.8) 32 (14.7) 18 (18.2) 0.50
Chronic liver disease 41 (12.9) 27 (12.4) 14 (14.1) 0.74
Solid organ transplantation 27 (8.5) 19 (8.7) 8 (8.1) 1
Hematological malignancy 20 (6.3) 16 (7.3) 4 (4.0) 0.32
Hematopoietic stem cell transplantation 9 (2.8) 8 (3.7) 1 (1.0) 0.28
Risk factors for candidemia
Previous antibiotic therapy 297 (93.6) 202 (92.7) 95 (96.0) 0.32
Central venous catheter 225 (71.0) 150 (68.8) 75 (75.8) 0.23
TPN during candidemia 158 (49.8) 101 (46.3) 57 (57.6) 0.07
Previous corticosteroid therapy 72 (22.7) 51 (23.4) 21 (22.1) 0.77
Abdominal surgery 85 (26.8) 52 (23.9) 33 (33.3) 0.10
Immunosuppressive therapy 47 (14.8) 36 (16.5) 11 (11.1) 0.23
Neutropenia 10 (3.2) 9 (4.1) 1 (1.0) 0.18
Previous antifungal treatment 49 (15.4) 37 (17.0) 12 (12.1) 0.32
Source of infection
Central venous catheter 141 (44.5) 101 (46.3) 40 (40.4) 0.33
Primary 98 (30.9) 73 (33.5) 25 (25.3) 0.15
Abdomen 39 (12.3) 19 (8.7) 20 (20.2) 0.006
Urinary tract 23 (7.3) 18 (8.3) 5 (5.1) 0.36
Infective endocarditis 3 (0.9) 1 (0.5) 2 (2.0) 0.23
Other 13 (4.1) 6 (2.8) 7 (7.1) 0.12
Candida species
C. albicans 134 (42.3) 91 (41.7) 43 (43.4) 0.80
C. glabrata 58 (18.3) 38 (17.4) 20 (20.2) 0.63
C. parapsilosis 55 (17.4) 40 (18.3) 15 (15.2) 0.52
C. tropicalis 29 (9.1) 22 (10.1) 7 (7.1) 0.52
C. krusei 6 (1.9) 4 (1.8) 2 (2.0) 1
C. lusitaniae 4 (1.3) 2 (0.9) 2 (2.0) 0.59
C. auris 27 (8.5) 18 (8.3) 9 (9.1) 0.86
Other 13 (4.1) 11 (5.0) 2 (2.0) 0.35
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therapy (65.3% vs 60.9%) or initial azole therapy (32.7% vs
39.1%) were comparable, patients with an intra-abdominal
origin received an adequate initial antifungal treatment
more often (38.1 vs 61.5, p = 0.008). No differences regard-
ing the rates of adequate source control (43.4% vs 40.5%,
p = 0.86) were observed between groups.
Prognostic factors for 30-day mortality
We compared candidemic patients who died at 30 days
(70 patients) with those who survived (247 patients).
Septic shock attributable to candidemia was present in
48.6% of patients who died (34/70) in comparison to
26.3% (65/247 patients) who survived (p = 0.001)
(Table 3). The Kaplan-Meier curves in Fig. 1 demon-
strate that patients with septic shock attributable to can-
didemia had a significantly greater likelihood of dying
compared to patients not developing septic shock at
candidemia onset.
Variables examined as risk factors for 30-day mortality
are presented in Table 3. Multivariate logistic regression
analysis demonstrated that a higher Charlson comorbid-
ity index and septic shock attributable to candidemia
and requiring hemodialysis after candidemia onset were
independently associated with greater 30-day mortality,
while CVC-related candidemia was independently asso-
ciated with a lower risk of 30-day mortality (Table 3).
Discussion
To the best of our knowledge, the current multicenter
study is the largest one to identify variables associated
with development of septic shock among patients with
Candida bloodstream infection. We found a significant
rate of septic shock among patients with candidemia
(30%), and we also demonstrated that age more than
50 years old and an intra-abdominal origin of the infec-
tion are the most important independent factors associ-
ated with septic shock development.
The incidence of septic shock is only collaterally men-
tioned in reports on candidemia in the general popula-
tions and it ranges from 12.9 to 49.0% in recent studies
[16–18]. However, only three series have specifically fo-
cused on the incidence of septic shock among candi-
demic patients. Patel et al. [19] in a single center
retrospective study that ended in 2007 documented sep-
tic shock in 23% of patients with candidemia. The preva-
lence was higher in two cohorts of critically ill patients
with candidemia in which septic shock developed in ~
35% of them [7, 20]. Ours is the first study to analyze
the prevalence of septic shock attributable to candide-
mia, in the light of the new Sepsis-3 definition [9]. With
these new criteria, we found that septic shock occurred
in almost one third of unselected candidemic patients.
We also found a significant difference in term of
prevalence between ICU patients and those admitted to
internal medicine and surgical ward, with a nearly two
times greater proportion of septic shock in ICU patients.
Although such difference was not unexpected, an
underestimation of the number of cases of septic
shock outside ICU should not be excluded. Regarding
this aspect, new Sepsis-3 definitions showed low sen-
sitivity in non-critically ill patients and performed
poorly as a screening tool for early identification of
sepsis outside ICU [21–23] Moreover, many patients
admitted to internal medicine and surgical ward are
frequently affected by multiple pre-existing underlying
diseases [24–28]. In such circumstance, worsening of
clinical conditions can be often misled to the progres-
sion of the underlying disease rather than to infec-
tion, as suggested by the low number of patients who
were admitted to ICU after candidemia onset in our
study (~ 7%).
Factors predisposing candidemic patients to develop
septic shock have been reported in just one retrospective
study including only 15 patients with septic shock [7].
Table 1 Comparison of the main demographic and clinical characteristics of study population (Continued)
Variable All episodes, N = 317 (%) Non-septic shock, N = 218 (%) Septic shock, N = 99 (%) p value
Resistant strains
Fluconazole 45 (14.1) 29 (13.3) 16 (16.2) 0.73
Echinocandins 3 (0.9) 2 (0.9) 1 (1.0) 1
BSI bloodstream infection, IQR interquartile range, SD standard deviation, TPN total parenteral nutrition
Table 2 Risk factors for development of septic shock at candidemia onset. Multivariate analysis
Variable Odds ratio 95% confidence interval p value
Age > 50 years 2.57 1.03–6.41 0.04
Intra-abdominal source of the infection 2.18 1.04–4.55 0.04
Male sex 1.33 0.78–2.26 0.29
Charlson comorbidity index 0.99 0.91–1.10 0.92
General ward stay at the time of candidemia onset 0.21 0.12–0.44 0.001
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Table 3 Risk factors for 30-day mortality (univariate and multivariate analysis)
Variable All episodes, N = 317 (%) Alive, N = 247 (%) Died, N = 70 (%) p OR 95% CI p
Demographics
Sex, male 184 (58.0) 154 (62.3) 46 (61.4) 0.89 – – –
Age ≥ 50 years 275 (86.8) 212 (85.8) 63 (90.0) 0.43 – – –
Mean age (± SD), years 65.4 ± 17.0 64.8 ± 16.8 67.2 ± 17.7 0.30 – – –
Median hospital stay until
Candida BSI (IQR), days
16 (7–31) 15 (6–29) 20 (10–34) 0.09 – –
Hospital ward
General ward 254 (80.1) 201 (84.1) 47 (67.1) 0.003 1.9 0.93–4.30 0.78
Intensive care unit 63 (19.9) 38 (15.9) 23 (32.9)
Charlson comorbidity index 3.4 ± 2.7 3.0 ± 2.4 4.6 ± 3.1 < 0.001 1.28 1.13–1.45 < 0.001
Underlying condition
Solid tumor 114 (35.9) 91 (36.8) 23 (32.9) 0.57 – – –
Cardiovascular disease 102 (32.2) 72 (29.1) 30 (42.9) 0.04 – – –
Diabetes mellitus 90 (28.4) 68 (27.5) 22 (31.4) 0.55 – – –
Chronic lung disease 51 (16.1) 36 (14.6) 15 (21.4) 0.20 – – –
Chronic kidney failure 50 (15.8) 36 (14.6) 14 (20.0) 0.27 – – –
Chronic liver disease 41 (12.9) 26 (10.5) 15 (21.4) 0.02 – – –
Solid organ transplantation 27 (8.5) 22 (8.9) 5 (7.1) 0.81 – – –
Hematological malignancy 20 (6.3) 15 (6.1) 5 (7.1) 0.78 – – –
Hematopoietic stem cell transplantation 9 (2.8) 6 (2.4) 3 (4.3) 0.41 – – –
Risk factors for candidemia
Previous antibiotic therapy 297 (93.6) 232 (93.9) 65 (92.9) 0.78 – – –
Central venous catheter 225 (71.0) 171 (69.2) 54 (77.1) 0.23 – – –
TPN during candidemia 158 (49.8) 118 (47.8) 40 (57.1) 0.17 – – –
Previous corticosteroid therapy 72 (22.7) 53 (21.5) 19 (27.1) 0.33 – – –
Abdominal surgery 85 (26.8) 65 (26.3) 20 (28.6) 0.76 – – –
Immunosuppressive therapy 47 (14.8) 39 (15.8) 8 (11.4) 0.45 – – –
Neutropenia 10 (3.2) 7 (2.8) 3 (4.3) 0.46 – – –
Previous antifungal treatment 49 (15.4) 37 (15.0) 12 (17.1) 0.71 – – –
Source of infection
Central venous catheter 141 (44.5) 122 (49.9) 19 (27.1) 0.001 0.42 0.20–0.88 0.02
Primary 98 (30.9) 71 (28.7) 27 (38.6) 0.14 – –
Abdomen 39 (12.3) 22 (8.9) 17 (24.3) 0.001 1.89 0.76–4.66 0.17
Urinary tract 23 (7.3) 22 (8.9) 1 (1.4) 0.03 0.11 0.12–1.02 0.05-
Infective endocarditis 3 (0.9) 3 (1.2) 0 (0) 1 – – –
Other 13 (4.1) 7 (2.8) 6 (8.6) 0.05 – – –
Septic shock 99 (31.2) 65 (26.3) 34 (48.6) 0.001 2.14 1.08–4.24 0.02
Initial adequate antifungal therapy 130 (41.0) 95 (38.5) 35 (50.0) 0.09 1.41 0.71–2.81 0.32
Adequate source control of the infection* 124/288 (43.1) 94/225 (41.8) 30/63 (47.6) 0.47 1.68 0.84–3.35 0.14
Hemodialysis after candidemia onset 7 (2.2) 2 (0.8) 5 (7.1) 0.007 8.55 1.35–53.95 0.02
*The source of the infection was susceptible of control in 288 patients
BSI bloodstream infection, IQR interquartile range, SD standard deviation, TPN total parenteral nutrition
Bassetti et al. Critical Care          (2020) 24:117 Page 6 of 9
Reflecting this weakness, this study identified no conven-
tional factors associated with septic shock development
other than the time spent in ICU before candidemia onset.
Our data suggest that, apart from older age, the only
variable associated with septic shock in candidemic pa-
tient was an intra-abdominal origin of the infection. This
result supports recent experimental observations that in-
testinal abundance of Candida may be associated with an
increased sepsis severity, perhaps through cytokine storm
induction and/or decreased macrophage killing activity
[29–31]. The fact that patients with other source of the in-
fection (i.e., CVC or urinary tract) received a similar rate
of adequate source control of candidemia (43.4% vs 40.5%,
p = 0.86) and even a lower rate of adequate antifungal
treatment (38.1% vs 61.5%, p = 0.008) is further consistent
with this intriguing explanation. Although we do not have
clear answer regarding to the best approach for reducing
the incidence of septic shock in candidemic patients, we
believe that new diagnostic strategies investigating the role
of serological biomarkers such as β-D-glucan or T2MR
[32–35] should be applied in order to early identify pa-
tients at risk of intra-abdominal candidiasis. Future studies
addressing risk factors for developing intra-abdominal
candidiasis are also needed to better clarify the best em-
piric or pre-emptive therapeutic approach.
With regard to Candida species as predisposing factor,
Guzman et al. did [36] not find any significant differ-
ences [7]. Despite our study including 27 episodes of C.
auris candidemia (8.5%) that is typically associated with
a high degree of virulence [37], we confirm previous
results, thus suggesting that host factors may be more
important than intrinsic factors of organisms. Antifungal
resistance was not an issue predisposing to septic shock
in our study, since only 14.1% of the patients had flucon-
azole resistant strains and half of them received ad-
equate definitive antifungal treatment.
Of interest, in the present report, the overall 30-day
mortality rate in patients with septic shock attributable
to candidemia was 34.3%, which is significantly lower
than that observed in two previous studies performed in
Europe and St. Louis, where mortality rate remained
around 50–60% [4, 5]. The difference in septic shock
definitions [9], improvements in fungal diagnosis [33,
34], and the widespread implementation of sepsis bundle
in recent years [38–40] may explain the lower incidence
of mortality observed in this study.
As for risk factors for mortality, our findings are consist-
ent with those recently reported by other investigators
[41] who found increased severity of the underlying condi-
tions (higher Charlson comorbidity index), clinical presen-
tation of candidemia (septic shock), and signs of organ
dysfunction (hemodialysis after candidemia onset) as risk
factors for late mortality (30 days after candidemia onset).
Although ours is the largest study published to date re-
garding variables associated with septic shock in candi-
demic patients, it has some limitations that should be
addressed. We only examine patients who develop septic
shock within the first 24 h from the first positive blood
culture for Candida. Therefore, we cannot rule out that
some patients presented with a septic shock in a later
Fig. 1 Thirty-day mortality of candidemic patients according to the development or not of septic shock, log rank ≤ 0.001
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stage of the infection. Furthermore, we did not include, in
the risk factors analysis for mortality, other core elements
of general supportive care that are crucial for an adequate
septic shock management (need for mechanical ventila-
tion, use of intravenous fluids and oxygen therapy). There-
fore, additional studies specifically designed to investigate
risk factors predicting septic shock development in pa-
tients with candidemia may be useful to assess the repro-
ducibility of our results.
Conclusions
An abdominal source of the infection is the most important
factor significantly associated with the development of sep-
tic shock attributable to candidemia. In view of the prog-
nostic implication of septic shock development, our results
lead us to consider an appropriate stratification of candi-
demic patients on the basis of the source of the infection.
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